Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors

PURPOSE: Claudin-6 (CLDN6) is expressed at elevated levels in multiple human cancers including ovarian and endometrial malignancies, with little or no detectable expression in normal adult tissue. This expression profile makes CLDN6 an ideal target for development of a potential therapeutic antibody...

Descripción completa

Detalles Bibliográficos
Autores principales: McDermott, Martina S.J., O'Brien, Neil A., Hoffstrom, Benjamin, Gong, KeWei, Lu, Ming, Zhang, Jun, Luo, Tong, Liang, Min, Jia, Weiping, Hong, Jenny J., Chau, Kevin, Davenport, Simon, Xie, Bin, Press, Michael F., Panayiotou, Richard, Handly-Santana, Abram, Brugge, Joan S., Presta, Leonard, Glaspy, John, Slamon, Dennis J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Translational Cancer Mechanisms and Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10233360/
https://www.ncbi.nlm.nih.gov/pubmed/36884217
http://dx.doi.org/10.1158/1078-0432.CCR-22-2981

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10233360/
https://www.ncbi.nlm.nih.gov/pubmed/36884217
http://dx.doi.org/10.1158/1078-0432.CCR-22-2981

Ejemplares similares